Payment overview · 2025
General Payments
$624.22
5 reported records · 4 companies
Healthcare provider profile · identity verified
Lea L Clark
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · YATES CITY, IL · NPI 1255910386
Verified facts
What the public records show
CMS Open Payments records show Lea L Clark received $624.22 in general payments during 2025 across 5 reported records.
Novo Nordisk Inc accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $249.89 | 40.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $130.18 | 20.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $124.26 | 19.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $119.89 | 19.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $624.22 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $130.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.89 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $124.26 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 350 | 122 |
| Lisinopril | Lisinopril | 203 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 80 |
| Gabapentin | Gabapentin | 190 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 68 |
| Omeprazole | Omeprazole | 162 | 63 |
| Losartan Potassium | Losartan Potassium | 127 | 52 |
| Tramadol Hcl | Tramadol Hcl | 122 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 37 |
| Metformin Hcl | Metformin Hcl | 93 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 31 |
| Furosemide | Furosemide | 89 | 35 |
| Alendronate Sodium | Alendronate Sodium | 75 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 25 |
| Sertraline Hcl | Sertraline Hcl | 70 | 22 |
| Trazodone Hcl | Trazodone Hcl | 69 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 24 |
| Lorazepam | Lorazepam | 59 | 15 |
| Buspirone Hcl | Buspirone Hcl | 58 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 19 |
| Simvastatin | Simvastatin | 50 | 21 |
| Prednisone | Prednisone | 48 | 38 |
| Eliquis | Apixaban | 47 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 19 |
| Potassium Chloride | Potassium Chloride | 47 | 19 |
| Meloxicam | Meloxicam | 46 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Alprazolam | Alprazolam | 44 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 43 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 39 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 16 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 15 |
| Allopurinol | Allopurinol | 34 | 15 |
| Bupropion Xl | Bupropion Hcl | 34 | 17 |
| Ozempic | Semaglutide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Carvedilol | Carvedilol | 32 | 11 |
| Fenofibrate | Fenofibrate | 32 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Ondansetron Odt | Ondansetron | 30 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | 14 |
| Montelukast Sodium | Montelukast Sodium | 28 | 12 |
| Warfarin Sodium | Warfarin Sodium | 27 | 13 |
| Azithromycin | Azithromycin | 26 | 24 |
| Famotidine | Famotidine | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | 12 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $624.22 · 5 records | Novo Nordisk Inc | FARXIGA, NUCALA, Ohtuvayre, Ozempic, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error